Abstract
The great efforts of many researchers have brought down some of the barriers that exist to turn a good in vitro compound into a potential in vivo drug. The advent of pharmaceutical nanotechnology has allowed an arsenal of drugs with poor stability, low solubility, high off-target toxicity and other disadvantageous features, to be accessible as pharmaceutical products that could be administered to a patient. Nanotechnology was introduced in drug delivery very long ago, but has flourished with unprecedented intensity during the last twenty years and now a diversity of nano-based preparations are at clinical stage of development or already available in the market. Undoubtedly, nanotechnology plays a key role in future pharmaceutical development and pharmacotherapy. In the first part of this review, we have already discussed recent (2008-2012) patents on linear polymer-based nanosystems (nanogels, nanospheres and nanocapsules) applications to cancer therapy. Here, we have expanded such analysis to branched polymers (dendrimers), self-assembling nanomicelles and lipid-based nanocarriers.
Keywords: Anticancer drug therapy, dendrimers, lipid-based nanosystems, liposomes, micelles, nanostructured lipid carriers, patents, solid lipid nanocarriers.
Recent Patents on Anti-Cancer Drug Discovery
Title:Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
Volume: 9 Issue: 1
Author(s): María E. Ruiz, Melisa E. Gantner and Alan Talevi
Affiliation:
Keywords: Anticancer drug therapy, dendrimers, lipid-based nanosystems, liposomes, micelles, nanostructured lipid carriers, patents, solid lipid nanocarriers.
Abstract: The great efforts of many researchers have brought down some of the barriers that exist to turn a good in vitro compound into a potential in vivo drug. The advent of pharmaceutical nanotechnology has allowed an arsenal of drugs with poor stability, low solubility, high off-target toxicity and other disadvantageous features, to be accessible as pharmaceutical products that could be administered to a patient. Nanotechnology was introduced in drug delivery very long ago, but has flourished with unprecedented intensity during the last twenty years and now a diversity of nano-based preparations are at clinical stage of development or already available in the market. Undoubtedly, nanotechnology plays a key role in future pharmaceutical development and pharmacotherapy. In the first part of this review, we have already discussed recent (2008-2012) patents on linear polymer-based nanosystems (nanogels, nanospheres and nanocapsules) applications to cancer therapy. Here, we have expanded such analysis to branched polymers (dendrimers), self-assembling nanomicelles and lipid-based nanocarriers.
Export Options
About this article
Cite this article as:
Ruiz E. María, Gantner E. Melisa and Talevi Alan, Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems), Recent Patents on Anti-Cancer Drug Discovery 2014; 9 (1) . https://dx.doi.org/10.2174/1574891X113089990038
DOI https://dx.doi.org/10.2174/1574891X113089990038 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Monitoring the Pharmacokinetics of Pyridinium Aldoximes in the Body
Mini-Reviews in Medicinal Chemistry Neuro-Transmitters in the Central Nervous System & their Implication in Learning and Memory Processes
Current Medicinal Chemistry Evaluation of Two Recombinant Plasminogen Activators in Massive Pulmonary Embolism Model and Potato Carboxypeptidase Inhibitor (PCI) role in Inhibition of Thrombin Activatable Fibrinolysis Inhibitor TAFIa in Lungs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Watching Every Step of the Way: Junín Virus Attenuation Markers in the Vaccine Lineage
Current Genomics The Perils, Pitfalls and Opportunities of Using High Sensitivity Cardiac Troponin
Current Medicinal Chemistry Editorial (Thematic Issue: Patent Ductus Arteriosus in Extremely Premature Neonates)
Current Pediatric Reviews New Patents on Topical Anesthetics
Recent Patents on Inflammation & Allergy Drug Discovery Angiotensin II-Vasopressin Interactions in The Regulation of Cardiovascular Functions. Evidence for an Impaired Hormonal Sympathetic Reflex in Hypertension and Congestive Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Pediatric Abdominal Trauma
Current Pediatric Reviews Effects of Alcohol in the Lung
Current Respiratory Medicine Reviews Determination of Phenolic Compounds’ Extraction Conditions from Pistacia palaestina Leaves at Two Different Stages of Maturity
Current Nutrition & Food Science Recent Progress of Imaging Agents for Parkinson’s Disease
Current Neuropharmacology Modulation of Potassium Channels as a Therapeutic Approach
Current Pharmaceutical Design Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation
Current Pharmaceutical Design Mechanisms Involved in Apoptosis Events Contributing to Sepsis-Induced Myocardial Dysfunction
Current Drug Therapy Atypical Antipsychotics: Pharmacokinetics, Therapeutic Drug Monitoring and Pharmacological Interactions
Current Medicinal Chemistry Neonatal Systemic Thrombosis: An Updated Overview
Current Vascular Pharmacology Pharmacogenetics of Antihypertensive Therapies: Can this be Applied in the Clinic?
Current Pharmacogenomics and Personalized Medicine Role of Omega-3PUFA: A Nutraceutical for Brain Functioning and Treatment of Mental Disorders
Current Indian Science Progress in Syntheses of 3-n-Butylphthalide and Its Analogues
Current Organic Chemistry